Page 2 - Natco Pharma

Fancy dividends? Keep an eye on these 11 stocks today; check full list here

Here is the complete list of stocks that will remain in focus today as they trade ex-dividend on August 19, along with their key details

Dr Reddy's Labs, Lupin: Nifty Pharma slips 2% amid Trump tariff jitters

Nifty Pharma index declined 1.5 per cent in trade after US President Donald Trump warned to impose a 25 per cent tariff on Indian goods starting August 1

Natco Pharma offers to acquire 35% in Adcock Ingram for ₹2,000 crore

The proposed Rs 2,000 crore deal will give Natco Pharma a strategic foothold in South Africa, with transaction completion expected within four months subject to approvals

Stock calls, July 4: Natco Pharma, Sharda Cropchem among top stocks to buy

Stocks to buy: Analyst pick Sharda Cropchem, Monarch Networth Capital and one more share to buy; Check full details

Why did Natco Pharma's share price slip 3% in trade today? Details here

Natco Pharma shares slipped in trade after the company said that the USFDA has issued one (1) observation in the Form-483 for its API manufacturing plant in Mekaguda, Hyderabad.

Stocks to Watch today, June 16, 2025: Ireda, DLF, OMCs, IndusInd Bk

Stocks to Watch today, June 16, 2025: From Ireda to oil-linked stocks, here is a list of few shares that will remain on investors' radar today

Here's why Natco Pharma share price is buzzing in trade on Thursday, May 29

Natco Pharma share price rose on the back of a healthy March quarter of financial year 2025 (Q4FY25) results.

Delhi HC tells Natco Pharma to pause launch of generic version of Risdiplam

Roche had appealed against a single judge order of March 24 that had refused to stop Natco Pharma from manufacturing a generic version of Risdiplam

Natco Pharma trades lower for 10th straight day; tanks 40% on weak Q3

The pharma stock hit its lowest level since December 2023 and tanked 52 per cent from its record high level of Rs 1,638.35, touched on September 12, 2024.

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Nifty Pharma index slips 3%; Natco, Glenmark, Lupin, Laurus down up to 10%

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.

Natco Pharma shares tank 19%, near 52-week low on weak Q3 results

During the quarter, contribution from the export formulation business was lower; however, the company expects healthy business growth in the ensuing quarters

Natco Pharma Q2FY25 results: PAT jumps 83% to Rs 676 cr on robust sales

Natco Pharma on Tuesday said its consolidated net profit jumped 83 per cent on-year to Rs 676 crore in the September 2024 quarter, aided by robust sales. The drug maker reported a net profit of Rs 369 crore in the July-September period of last fiscal. Revenue from operations rose to Rs 1,371 crore as compared with Rs 1,031 crore in the year-ago period, the company said in a regulatory filing. "The company has shown continued strong growth during the second quarter driven by exports formulation business and stable domestic pharmaceutical business," it stated. The company said its board has declared a second interim dividend of Rs 1.5 per equity share of Rs 2 each for financial year 2024-25. Shares of the drug firm ended 0.19 per cent down at Rs 1,393.15 apiece on the BSE.

Here's why Natco Pharma share price gained over 4% on October 7; details

Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide)

Natco Pharma shares hit all time high, extend gain for second day; details

The Natco Pharma share price has surged nearly 20 per cent in the last one month, and by 92 per cent year to date

Natco Pharma stock rises 3% after subsidiary invests $8 mn in biotech firm

Natco Pharma share price rose after the company on Wednesday announced that its wholly owned Canadian subsidiary, NATCO Pharma Inc, has made an investment of $8 million in eGenesis

Natco Pharma rises 4% after filing ANDA for generic lung cancer drug

Natco Pharma is the first company to have filed a substantially complete ANDA for a generic cancer drug

Natco Pharma stock surges 8%, hits new 52-week high on strong Q4 show

On Monday, Natco Pharma reported a 40.1 per cent year-on-year (YoY) surge in net profit, totaling Rs 386.3 crore in Q4FY23, up from Rs 275.8 crore

Q4 results today: LIC, NMDC, AstraZeneca among 303 firms to post earnings

Q4 FY24 company results: Elgi Equipments, Natco Pharma, Nalco, Goodyear India, and IFB Ind will be releasing their fourth quarter report on May 27

USFDA pulls up Natco Pharma for several violations at Telangana plant

Natco Pharma failed to maintain cleanliness, sterilise equipment and utensils at appropriate intervals at its Telangana-based plant, as per the US health regulator. In the warning letter to the company, US Food and Drug Administration said its investigators observed various violations at the finished pharmaceuticals plant located at Kothur Village in Telangana. The USFDA inspected the facility from October 9 to 18, 2023. "Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and/or sterilise equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements," the US health regulator noted. It further said: "Your cleaning procedure for your non-dedicated equipment is inadequate." Cross-contamination is not uniform, and the testing of control samples and placebo batches failed to ...